1. Model-based optimization of combination protocols for irradiation-insensitive cancers
- Author
-
Tomasz Lipniacki, Beata Hat, and Joanna Jaruszewicz-Błońska
- Subjects
medicine.medical_treatment ,lcsh:Medicine ,Antineoplastic Agents ,Apoptosis ,Radiation Tolerance ,Article ,Targeted therapy ,Neoplasms ,medicine ,Humans ,PTEN ,lcsh:Science ,Cells, Cultured ,Cancer ,Cell Proliferation ,Models, Statistical ,Multidisciplinary ,biology ,Chemistry ,Cell growth ,lcsh:R ,PTEN Phosphohydrolase ,Dose-Response Relationship, Radiation ,Proto-Oncogene Proteins c-mdm2 ,Chemoradiotherapy ,medicine.disease ,Protein Phosphatase 2C ,Dose–response relationship ,Gamma Rays ,Cancer cell ,Cancer research ,biology.protein ,Mdm2 ,lcsh:Q ,Tumor Suppressor Protein p53 ,Systems biology - Abstract
Alternations in the p53 regulatory network may render cancer cells resistant to the radiation-induced apoptosis. In this theoretical study we search for the best protocols combining targeted therapy with radiation to treat cancers with wild-type p53, but having downregulated expression of PTEN or overexpression of Wip1 resulting in resistance to radiation monotherapy. Instead of using the maximum tolerated dose paradigm, we exploit stochastic computational model of the p53 regulatory network to calculate apoptotic fractions for both normal and cancer cells. We consider combination protocols, with irradiations repeated every 12, 18, 24, or 36 h to find that timing between Mdm2 inhibitor delivery and irradiation significantly influences the apoptotic cell fractions. We assume that uptake of the inhibitor is higher by cancer than by normal cells and that cancer cells receive higher irradiation doses from intersecting beams. These two assumptions were found necessary for the existence of protocols inducing massive apoptosis in cancer cells without killing large fraction of normal cells neighboring tumor. The best found protocols have irradiations repeated every 24 or 36 h with two inhibitor doses per irradiation cycle, and allow to induce apoptosis in more than 95% of cancer cells, killing less than 10% of normal cells.
- Published
- 2020
- Full Text
- View/download PDF